Ocular Blood Flow Imaging for Glaucoma Assessment
Who can join
As published by the study on ClinicalTrials.gov. "Not stated" means the study hasn't said — ask the study team.
- Age
- 18 Years to 88 Years
- Sex
- All sexes
- Healthy volunteers
- Accepted
- Compensation
- Not stated
Other requirements are listed under Eligibility below. Only the study team can confirm whether you can join.
What to expect
No one can promise a trial will help you personally — that is what the research is trying to find out.
What participation involves
Not stated in the study description — ask the study team about visits and procedures.
- Compensation
- Not stated
- Study-related exams and procedures are typically provided at no cost. This is how many trials work in general — confirm the details for this study with the study team.
- Participants are monitored closely by the research team throughout the study.
- Some participants may receive access to an investigational treatment, which is still being studied.
- Your participation helps researchers learn whether this approach could help future patients.
About this study
In plain language
This study tests whether XyCAM eye imaging tools can use blood flow to help spot early glaucoma, an eye disease that damages the nerve used for sight. It also tests whether XyCAM FC can take 3D pictures of the back of the eye while measuring blood flow. Adults with healthy eyes, those referred for a glaucoma check, and those with moderate to severe glaucoma may join.
The goal of this clinical trial is to investigate the use of an FDA-cleared retinal blood flow imaging instrument called the XyCAM RI and XyCAM FC (Vasoptic Medical, Inc., Columbia, MD) in glaucoma management. The main question it aims to answer are: * Can the investigators use blood flow to discriminate between eyes with early-stage glaucoma and variable-matched controls? * Can the investigators validate that the XyCAM FC simultaneously captures both stereo fundus photography and ocular blood flow monitoring? Participants will be * measured for their blood pressure, heart rate, height, and weight * dilated with tropicamide * imaged using the XyCAM RI, fundus photography, optical coherence tomography, and standard automated perimetry * imaged using the XyCAM RI while inhaling 100% oxygen through a mask
Compensation is read from the study's own description and may be missing — always confirm with the study team.
Eligibility
Who can join
- Age 18 or older and able to see with both eyes.
- Able to understand the study and agree to take part.
- Have healthy eyes, have been referred for a glaucoma check, or have moderate to severe glaucoma in at least one eye based on the study's grading rules.
Who can't join
- Have clouding or scarring that blocks a clear view inside the eye, such as a major cataract or a scar on the clear front of the eye.
- Have had eye surgery other than cataract removal without problems, laser treatment to help drain eye fluid (ALT or SLT), or laser treatment to clear clouding after cataract surgery (YAG).
- Have had an eye disease other than glaucoma.
- Have narrow drainage angles in the eyes, or have had a bad reaction to tropicamide eye-widening drops or fluorescein dye.
- Need more than 15 diopters of vision correction, a measure of lens strength.
- Are pregnant or breastfeeding.
- Have diabetes.
Simplified for readability. The official criteria below are what the study team uses.
Official eligibility criteria
Inclusion Criteria: * Age 18 and older with binocular vision * Able to provide informed consent * Patient is a healthy control OR is recommended for glaucoma assessment OR diagnosed with moderate to severe glaucoma in at least one eye as determined by Hodapp Anderson Criteria Exclusion Criteria: * The subject has significant media opacity (e.g., a visually significant cataract or significant corneal scar) * The subject has previous ocular surgery other than uncomplicated cataract extraction, laser trabeculoplasty (ALT or SLT), or YAG capsulotomy * The subject has prior ocular disease other than glaucoma * The subject has anatomically narrow angles or a prior adverse reaction to administration of Tropicamide or fluorescein dye * The subject has more than 15 diopters of refractive error * The subject is a female who is pregnant or nursing * The subject has diabetes mellitus
Study sites (1)
MD
- University of Maryland Eye Associates at Redwood · Baltimore, MD 21201Osamah Saeedi, MD, MS · Study contactMore trials in Baltimore